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Background
S179D prolactin (S179D PRL) is a pseudophosphorylated
form of human prolactin (PRL) which has inhibitory
effects on tumor growth [1] and angiogenesis [2]. The
S179D PRL preparations used for these experiments con-
sisted of properly refolded inclusion bodies (IB) from
Escherichia coli [3]. Trying to attain a better folded mutant,
we used secretion expression based systems. However,
single point mutations can affect protein periplasmic
expression [4], and secretion from mammalian cells [5].
We observed that upon a mutation of Serine 179 to an
Aspartate, expression was nearly abolished when com-
pared with PRL in E. coli periplasm, while the cytoplasmic
product was more prone to proteolysis. Using eukaryotic
cells we were able to produce preparations comparable to
IBs in terms of bioactivity. We also demonstrated that this
mutant had a higher affinity for heparin and lower bind-
ing capacity towards divalent metals (M (II)).
Results
S179D PRL periplasmic expression was very low when
compared to PRL. Use of different promoters, different
signal peptides or different activation temperatures had
no effect (figure 1).
MALDI-TOF spectrometry was carried out for identity of
S179D PRL in the extracts (figure 2).
BL21 strain was used (figure 1B) without improvements
for S179D PRL expression (table 2).
We used BL 21 codon plus® in order to investigate the GC-
, AT-rich sequence of the PRLs influence on expression.
This strain did not rescue expression of S179D PRL or PRL
(figure 1C). pTac induction at lower temperatures should
encourage protein solubility and folding in the cytoplasm
[6]. We carried out cytoplasmic expression with an Ori-
gami B strain, in which cytoplasm folding is facilitated [7].
Surprisingly, when S179D PRL was produced in soluble
form, unlike PRL, low molecular forms were observed
(figure 3A and 3B), and also in BL21, cleaved forms and
soluble high molecular aggregates were present (figure
3A). pL constructs had very low yields for both PRLs (fig-
ure 3).
An eukaryotic expression system was chosen to success-
fully produce soluble, monomeric, recombinant S179D
PRL.
B-casein bioassays were carried out to check S179D PRL
folding. (figure 5).
Moreover S179D PRL had a decreased affinity towards Ni
(II) ans Zn (II). On the other hand it had an increased
affinity towards heparin.
Conclusion
We tried to produce a correctly folded form of S179D PRL,
already obtained as refolded IBs [3]. Unexpectedly, this
point mutation of PRL impaired protein expression, and
was not related to the strain, protease degradation of our
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Molecular masses determined by MALDI-TOF-MSFigure 2
Molecular masses determined by MALDI-TOF-MS.
A, B and C, Immunoblots of periplasmic extractsFigure 1
A, B and C, Immunoblots of periplasmic extracts.
Microbial Cell Factories 2006, 5(Suppl 1):P17protein, or preferential codon usage (figure 1). To avoid
proteolysis and misfolding we used lower temperatures
during protein production [8], but it failed to produce
S179D PRL. Low levels of S179D PRL were only detected
by immunoblots (figure 1) and by immunoassay (table
1). Expression of soluble S179D PRL in the cytoplasm of
E.coli was not efficient either, as denoted by soluble aggre-
gates and cleaved S179D PRLs. Eukaryotic expression sys-
tems have a better folding machinery, being difficult-to-
fold proteins more easily expressed [9]. Thus, we success-
fully produced S179D PRL at RP-HPLC detectable levels
(figure 4). MALDI-TOF analysis showed that all samples
had the expected molecular weight (figure 2). RP-HPLC
demonstrated that S179D PRL had a different folding
than PRL. The bioactivity assay showed that all prepara-
tions of S179D PRL were correctly folded. S179D PRL also
showed physical-chemical differences, having a lower M
(II)-affinity and a higher heparin-affinity. This confirms
reports of PRL mutants with low Zn (II) affinity that are
poorly secreted [4] and also could account for its anti-ang-
iogenic effect [2,10].
Immunoblots of soluble fractions of E. coli lysatesFigure 3
Immunoblots of soluble fractions of E. coli lysates.
Table 1: Protein expression yield (μg/mL/OD) and final optical densities (OD600) of different strains with pL promoter.
E. colistrain Protein yield (μg/mL/OD) Final OD600
PRL W3110 1.3 ± 0.2 4.0 ± 0.3
BL21 1.9 ± 0.4 1.3 ± 0.2
BL21 codon plus 1.4 ± 0.3 1.0 ± 0.2
S179D PRL W3110 0.34 ± 0.03 3.8 ± 0.6
BL21 0.35 ± 0.5 1.3 ± 0.5
BL21 codon plus 0.40 ± 0.3 1.2 ± 0.1Page 3 of 4
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β-casein bioassayFigure 5
β-casein bioassay. * p < 0.05 versus control; ** p < 0.01 ver-
sus control. AU, arbitrary unit.
Immunoblot of conditioned medium. B, C, RP-HPLC analysisFigure 4
Immunoblot of conditioned medium. B, C, RP-HPLC analysis.Page 4 of 4
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